Quick Answer
Allogene Therapeutics, Inc. reported Total Revenue of $0.00 for the year ending 2025.
- Allogene Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.00 | Q2 2020: $0.00 | Q3 2020: $0.00 | Q1 2021: $38.35 million | Q2 2021: $44.0 thousand | Q3 2021: $49.0 thousand | Q1 2022: $39.0 thousand | Q2 2022: $64.0 thousand | Q3 2022: $27.0 thousand | Q1 2023: $30.0 thousand | Q2 2023: $22.0 thousand | Q3 2023: $22.0 thousand | Q1 2024: $22.0 thousand | Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $0.00 | Q2 2025: $0.00 | Q3 2025: $0.00.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $22.0 thousand | Fiscal year 2023: $95.0 thousand | Fiscal year 2022: $156.0 thousand | Fiscal year 2021: $114.09 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: